131123-76-7 Hazards Identification
Pictogram(s):
Signal:
Warning
GHS Hazard Statements:
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
Precautionary Statement Codes:
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501
Hazard Classes and Categories:
Skin Irrit. 2 (100%)
Eye Irrit. 2 (100%)
STOT SE 3 (100%)
131123-76-7 Usage
Uses
5,7-Dichlorokynurenic acid is a potent NMDA receptor glycine binding site antagonist.
Biological Activity
Potent antagonist at the glycine site of the NMDA receptor (K i = 79 nM vs. [ 3 H]-glycine).
Check Digit Verification of cas no
The CAS Registry Mumber 131123-76-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,1,2 and 3 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 131123-76:
(8*1)+(7*3)+(6*1)+(5*1)+(4*2)+(3*3)+(2*7)+(1*6)=77
77 % 10 = 7
So 131123-76-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)
131123-76-7Relevant academic research and scientific papers
2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS
-
Page 44, (2010/02/07)
Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
Platelet adenosine diphosphate receptor antagonists
-
, (2008/06/13)
Compounds of the following formula (I): where a, b, R1, R2, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, met
